Advanced search
Publication Cover
Cancer Biology & Therapy Volume 13, 2012 - Issue 5
Submit an article Journal homepage
634
Views
15
CrossRef citations to date
0
Altmetric
Research Paper

Evaluation of checkpoint kinase targeting therapy in Acute Myeloid Leukemia with complex karyotype

Christine Didier INSERM; 1037, Cancer Research Center of Toulouse; CNRS ERL 5294; Toulouse, France;; University of Toulouse; Toulouse, FranceCorrespondence[email protected]
,
Cécile Demur
,
Fanny Grimal CNRS; ITAV-UMS3039; Toulouse, France;; CHU de Toulouse; Service d’Hématologie; Toulouse, France;
,
Denis Jullien CNRS; ITAV-UMS3039; Toulouse, France;; CHU de Toulouse; Service d’Hématologie; Toulouse, France;
,
Stéphane Manenti
&
Bernard Ducommun CNRS; ITAV-UMS3039; Toulouse, France;; CHU de Toulouse; Service d’Hématologie; Toulouse, France;; University of Toulouse; Toulouse, France
Pages 307-313 | Received 18 Aug 2011, Accepted 15 Dec 2011, Published online: 01 Mar 2012

Citations (15)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Kamal Chamoun & Gautam Borthakur. (2018) Investigational CHK1 inhibitors in early stage clinical trials for acute myeloid leukemia. Expert Opinion on Investigational Drugs 27:8, pages 661-666.
Read now
Abdallah Abou Zahr & Gautam Borthakur. (2017) Emerging cell cycle inhibitors for acute myeloid leukemia. Expert Opinion on Emerging Drugs 22:2, pages 137-148.
Read now
Caroline Bret, Elena Viziteu, Alboukadel Kassambara & Jerome Moreaux. (2016) Identifying high-risk adult AML patients: epigenetic and genetic risk factors and their implications for therapy. Expert Review of Hematology 9:4, pages 351-360.
Read now

Articles from other publishers (12)

Jehad F. Alhmoud, Ayman G. Mustafa & Mohammed Imad Malki. (2020) Targeting DNA Repair Pathways in Hematological Malignancies. International Journal of Molecular Sciences 21:19, pages 7365.
Crossref
David A. Gillespie. 2018. Targeting the DNA Damage Response for Anti-Cancer Therapy. Targeting the DNA Damage Response for Anti-Cancer Therapy 209 240 .
Ian Collins & Michelle D. Garrett. 2018. Targeting the DNA Damage Response for Anti-Cancer Therapy. Targeting the DNA Damage Response for Anti-Cancer Therapy 241 276 .
A. Ghelli Luserna di Rora’, I. Iacobucci & G. Martinelli. (2017) The cell cycle checkpoint inhibitors in the treatment of leukemias. Journal of Hematology & Oncology 10:1.
Crossref
Jonathan A. Webster, Raoul Tibes, Larry Morris, Amanda L. Blackford, Mark Litzow, Mrinal Patnaik, Gary L. Rosner, Ivana Gojo, Robert Kinders, Lihua Wang, L. Austin Doyle, Catherine J. Huntoon, Larry M. Karnitz, Scott H. Kaufmann, Judith E. Karp & B. Douglas Smith. (2017) Randomized phase II trial of cytosine arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed and refractory acute myeloid leukemia. Leukemia Research 61, pages 108-116.
Crossref
Stuart Rundle, Alice Bradbury, Yvette Drew & Nicola Curtin. (2017) Targeting the ATR-CHK1 Axis in Cancer Therapy. Cancers 9:12, pages 41.
Crossref
Cyril Ronco, Anthony R. Martin, Luc Demange & Rachid Benhida. (2017) ATM, ATR, CHK1, CHK2 and WEE1 inhibitors in cancer and cancer stem cells. MedChemComm 8:2, pages 295-319.
Crossref
Maria Teresa Esposito & Chi Wai Eric So. (2014) DNA damage accumulation and repair defects in acute myeloid leukemia: implications for pathogenesis, disease progression, and chemotherapy resistance. Chromosoma 123:6, pages 545-561.
Crossref
Ling Li Yuan, Alexa Green, Laure David, Christine Dozier, Christian Récher, Christine Didier, Jérôme Tamburini & Stéphane Manenti. (2014) Targeting CHK1 inhibits cell proliferation in FLT3-ITD positive acute myeloid leukemia. Leukemia Research 38:11, pages 1342-1349.
Crossref
L L Yuan, A S Green, S Bertoli, F Grimal, V Mansat-De Mas, C Dozier, J Tamburini, C Récher, C Didier & S Manenti. (2013) Pim kinases phosphorylate Chk1 and regulate its functions in acute myeloid leukemia. Leukemia 28:2, pages 293-301.
Crossref
Yun Dai, Shuang Chen, Maciej Kmieciak, Liang Zhou, Hui Lin, Xin-Yan Pei & Steven Grant. (2013) The Novel Chk1 Inhibitor MK-8776 Sensitizes Human Leukemia Cells to HDAC Inhibitors by Targeting the Intra-S Checkpoint and DNA Replication and Repair. Molecular Cancer Therapeutics 12:6, pages 878-889.
Crossref
Judith E. Karp, Brian M. Thomas, Jacqueline M. Greer, Christopher Sorge, Steven D. Gore, Keith W. Pratz, B. Douglas Smith, Karen S. Flatten, Kevin Peterson, Paula Schneider, Karen Mackey, Tomoko Freshwater, Mark J. Levis, Michael A. McDevitt, Hetty E. Carraway, Douglas E. Gladstone, Margaret M. Showel, Sabine Loechner, David A. Parry, Jo Ann Horowitz, Randi Isaacs & Scott H. Kaufmann. (2012) Phase I and Pharmacologic Trial of Cytosine Arabinoside with the Selective Checkpoint 1 Inhibitor Sch 900776 in Refractory Acute Leukemias. Clinical Cancer Research 18:24, pages 6723-6731.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.